Project Grant R43AI145704

This is a Cooperative Agreement awarded by the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), to the Scripps Research Institute. The $490,396 award, dated August 20, 2024, supports the development of a novel live-attenuated vaccine platform for Lassa fever, a deadly viral disease endemic to West Africa. The project aims to comprehensively characterize and evaluate the safety, immunogenicity, and...

The Department of Agriculture Animal and Plant Health Inspection Service awarded Purdue University $2,729,261 under the Cooperative Agreement to develop surveillance tools and strategies for the rapid detection and characterization of new SARS-CoV-2 variants through May 2025. This funding supports research under the Plant and Animal Disease, Pest Control, and Animal Care federal grant program (CFDA 10.025) to create a molecular detection method and user-friendly dashboard for SARS-CoV-2...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support the development of a novel universal rapid test for HIV diagnosis. IGE Immunodiagnostics & Therapeutics, LLC, a minority-owned small business, will receive $294,948 to adapt their existing HIV ELISA test into a 5th generation antigen/antibody combination rapid test format. The goal is to create a simple, rapid,...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $504,703 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Georgia Research Foundation, Inc. The grant is for a 5-year project to optimize an ultra-sensitive PCR (ULTRAPCR) technique for detecting Trypanosoma cruzi, the parasite that causes Chagas disease. The goal is to develop ULTRAPCR as an improved diagnostic and treatment monitoring tool for Chagas disease in...

The National Science Foundation (NSF) awarded a $550,000 Project Grant under the NSF Technology, Innovation, and Partnerships (TIP) program to the University of California, Los Angeles (UCLA) to develop a rapid, multiplexed diagnostic tool for serological testing of tick-borne diseases (TBDs). This 2-year project seeks to improve blood-based detection of TBDs, including Lyme disease, Babesia, Anaplasma, and relapsing fever, through an innovative point-of-care (POC) serological assay. The goal is...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop an integrated biosensor technology for the simultaneous detection of HIV, hepatitis B, and hepatitis C viruses. The $537,619 award, spanning from March 2025 to February 2028, will support the University of Central Florida's research to integrate their recently developed four-way junction (4WJ) electrochemical...

This National Science Foundation (NSF) Small Business Innovation Research (SBIR) Phase I award to RT Microdx Inc. provides $274,362 to develop a novel molecular diagnostic platform for detecting respiratory diseases like strep throat. The platform aims to provide laboratory-level accuracy for home use by non-healthcare professionals, reducing the burden on healthcare facilities and improving access to rapid and reliable pathogen detection, especially in underserved areas. The project focuses...

This Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to address the growing syphilis epidemic and prevent congenital syphilis infections. The $212,357 project, to be completed by July 2026, has three key objectives: Develop a point-of-care nucleic acid test (POC NAT) on a microfluidic rapid and autonomous analytical device (MicroRAAD) with a colorimetric readout for...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $300,000.00 to Salus Discovery LLC to develop a next-generation urine-based lateral flow assay (LFA) for tuberculosis (TB) diagnosis in point-of-care settings. The project, titled "FLOW DIRECT: NEXT GENERATION URINE LFA FOR TB DIAGNOSIS IN POINT-OF-CARE SETTINGS", aims to address the critical gap in access to...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $246,000.00 to The University of Texas Southwestern Medical Center to conduct research on optimizing molecular polymerase chain reaction (PCR) testing for the diagnosis of congenital syphilis. The key objectives are to determine whether PCR can detect Treponema pallidum DNA in neonates exposed to maternal...